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Abstract
A study was carried out among. haemophiliacs in
The Netherlands to evaluate the effect of modern
Substitution treatment (replacing the missing
clotting factors) on medical and social performance.
Three questionnaires were sent between 1972 and
1985. The use of prophylactic treatment in the group
of patients with severe and moderately severe
haemophilia increased from 21% (n=242) in 1972 to
36% (n=559) in 1985. Home treatment programmes
increased from 4% to 53%. Overall mortality was
2-1 times higher than in the general male population,
which leads to a calculated life expectancy of 66
years compared with 74 years in the general male
population. Severe joint impairment was prominent
in the older age groups, reflecting insufficient
treatment in the past. A sharp decrease in the use of
inpatient and outpatient hospital facilities was
observed äs well äs much less absence from school
and work.
It is concluded that the high costs of modern
Substitution treatment are fully justified.
Introduction
Before modern Substitution treatment was intro-
duced at the end of the 1960s haemophilia caused
premature death and severe disability at a young
age. The possibility of a person with haemophilia
enjoying a füll social life was non-existent or limited.
The availability of clotting factor concentrates and the
introduction of home treatment have greatly improved
the quality of life of patients with haemophilia and
their families. The feelings of optimism that resulted
from this development have, however, gradually
disappeared with the occurrence of diseases that are
associated with transfusion, such äs hepatitis and
AIDS.
Unlike patients in hospital who receive a few or just
one transfusion with füll blood or blood components
haemophiliacs receive during their life many trans-
fusions of clotting factor VIII or IX, which they lack.
This so called Substitution or replacement treatment is
given on demand (when bleeding occurs) or äs a
prophylaxis. It is this repeated Substitution treatment
that makes haemophiliacs so susceptible to diseases
associated with transfusion, especially when the
clotting factor concentrates are made from large pools
ofdonor blood.
The side effects of transfusion, together with the
cost of treating haemophiliacs and the growing
pressure on health care budgets, may cause people to
question whether the benefits of Substitution treatment
still outweigh the disadvantages. A few studies only
have dealt with this question and they have been
limited to small numbers of patients or to one aspect—
for instance, the introduction of home treatment or
employment. Moreover, these studies concerned
single treatment networks so that the conclusions may
not be generalised.'6
The aim of our study was to evaluate modern
haemophilia treatment in The Netherlands. Therefore,
we reviewed the medical and social performance of
Dutch haemophiliacs by means of questionnaires sent
out in 1972,1978, and 1985.
Methods
We carried out three postal surveys among Dutch
haemophiliacs in 1972, 1978, and 1985. The first was
based on a haemophilia questionnaire used by the
Children's Orthopedic Hospital in Los Angeles,
California." The questionnaire was prestructured
(multiple choice) and had some open questions. The
standardised questionnaires covered a broad ränge
of aspects of haemophilia—for example, type and
severity, number of bleedings, transfusion treatment,
treatment regimens, orthopaedic state, hospital
admissions, education, disability and employment,
insurance, social relations, genetic counselling, and so
on. Many items were repeated in the second and third
surveys, while questions on some current topics, such
äs home treatment (second) and infection with HIV
(human immunodeficiency virus) (third) were added.
Patients or their parents were reached through the
Dutch Haemophilia Society, treatment centres, and
notices in the press. When necessary the information
from the patients' questionnaires was supplemented
with data from the haemophilia treatment centres.
Cumulative data refer to the one year period directly
preceding the mailing of the questionnaires.
Figures on mortality were calculated for the
respondents in either one or both of the first two
surveys, with follow up extending up to l January
1986. These formed a group of 717 patients; none was
lost to follow up. Mortality was calculated by life
table method and compared with the mortality of a
hypothetical cohort of the general male population
with a similar age distribution. These and other data
for the general male population were provided by the
Central Bureau for Statistics" and the Department of
Social Affairs and Employment.'
Joint impairment for 16 joints was scored äs follows:
0, no impairment of the joint; l, some impairment but
no daily problems; 2, impairment with daily problems;
3, impairment with complete loss of function. The
total score ranged from 0 to 48 points.
Of the 935 participants in the 1985 survey 567 (61%)
had also participated in one of the earlier surveys. Of
the 376 patients with mild haemophilia in the 1985
survey, 207 (55%) were new participants, in contrast to
91 (24%) and 70 (40%) patients with severe and
moderately severe haemophilia respectively. To allow
data from the three surveys to be compared we decided
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to exclude ihe patients with mild haemophiha irom ihe
analysis. We investigated whether a "healthier new
patients effect" still existed —that is, whether the
patients m the 1985 survey who had not participated in
the earlier surveys were healthier than those who had
participated before, which would of course lead to an
overoptimistic view. As a measure for comparison we
used the score on joint impairment, äs defined above.
Table I shows the score for joint impairment for
patients who were new participants and those who also
participated in 1972 or 1978, stratified by age. The
observed differences in joint score were small and not
significant (ρ<0·05).
r-\Bit i—Scores for joint impamnetit: panents participating jor ihe
first Urne (neu') in the 1985 sun'cy comparcd with those who
participated m orte oj the earlier survevs (old)
Old patients New patients
Age
t \ears)
10-19
20-34
35 +
No
86
159
144
Mean
störe
1 79
5 55
1040
No
36
27
29
Mean
score
1 SO
4 52
652
öl
means
0 29
1 03
3 88
Confidencc
inten al
-0-63 10 1 21
-1 01 t o 3 0 8
-1 12 to 6 58
\'olc The age groups were thosen to form about equal si/ed subgroups in
the "neu' patients group The \oungest patients uere extludcd since the\
eould not ha\ e participated in one of the earlier sur\ e\ s For all three age
groups the dilfercnces in the mean |omt scores Ά ere small and not significant
ip<0 051 äs the 9VO confidente inten al of the differente enelosed /ero
Results
Response—The response to the questionnaires
was 84% in 1972 (447 participants), 70% in 1978
(560 participants), and 81% in 1985 (935 participants
from 1162 questionnaires mailed). With an estimated
prevalence of 8-5 per 100000 population and a total
population of 14-5 million Dutch we reached more
than 90% of all Dutch haemophiliacs in 1985, and three
quarters responded to the survey.
In 1985, 801 (85%) respondents had haemophilia A,
132 (15%) haemophilia B, and two patients had a
factor VII and factor XIII deficiency, respectively.
This distribution was similar in the first two surveys.
In 1985, 384 (40%) had severe, 175 (20%) moderately
severe, and 376 (40%) mild haemophilia; 19 (5%)
patients with severe haemophilia had an inhibitor, and
another 12 mentioned that their one time inhibitor had
been eradicated.
Treatment—Both prophylactic treatment and home
treatment have increased enormously since 1972
(table II) in the group with severe and moderately
severe haemophilia. The average number of manifest
bleedings decreased from 19 a year in 1972 and 1978 to
13 a year in 1985, with a corresponding decline in
the number of transfusions needed for treatment
on demand. For comparison, those with mild haemo-
philia reported one bleed a year in 1985. In the group
with severe and moderately severe haemophilia
Substitution treatment for 495 (89%) patients consisted
of clotting factor concentrates prepared by the Dutch
Red Cross blood transfusion Services; 35 (6%) of the
TABLE n —Type of treatment given to patients with severe and
moderately severe haemophilia. Figures are numbers (and percenlages)
No treatment*
Treatment on demand
Proph>lactic treatment
Home treatment
1972
(n=242)
33(14)
157(65)
52(21)
9 (4)
1978
(n = 351)
34(10)
201(57)
116(33)
88(25)
1985
(n=559)
29 (5)
329 (59;
201 (36)
298(53)
respondents were treated with commercially produced
imported concentrates, whereas 29 received no
treatment. The market share of the commercially
produced imported concentrates proved somewhat
higher in the survey of 1978 but then declined,
probably owing to the risk of HIV infection.
Life expectancy—'Wt: found an overall mortality
(43 deaths) 2-1 times higher than would have occurred
in a group of non-haemophiliacs of the same age
distribution. This excess mortality in haemophilia
leads to a calculated median life expectancy of 66 years
(general male population: 74 years), when an equal
distribution of excess mortality over age is assumed.
Most improvement has been made in severe haemo-
philia, and now almost equal death rates apply for
severe, moderate, and mild haemophilia. Patients with
an inhibitor had a far less favourable prognosis, with a
risk of death five times higher than the severely
affected haemophiliacs without an inhibitor.'"
HIV—In our latest survey more than a third (134) of
all patients with severe haemophilia had been tested for
antibodies to HIV compared with 41 (23%) and 40
(11%) of the patients with moderately severe and mild
haemophilia, respectively. The overall seropositivity
was 17% (36 of 217), with the highest prevalence
(21 %) of HIV antibodies among patients with severe
haemophilia."
Joint impairment—Looking at the total score of joint
impairment in 1985 we saw that 58 (15%) of the
patients with severe haemophilia reported no joint
damage at all compared with 68 (39%) and 224 (60%) of
those with moderately severe and mild haemophilia.
14-
12-
- 8-1
CO 6-
4-
Severe
*Those who received no treatment betause of no blecdmgs, the presence of
an Inhibitor, or macccssibility of treatment fauhlics
10 15 20 25 30 35 40 45 50+
Age (years)
Joint impairment score by age of respondents with severe (n=384),
moderately severe (n=I75), and mild haemophilia (n=376) m 1985.
Median scores were calculated for five year age groups and are shown
at ihe mid-mterval poml. Panents aged over 50 were combined äs
"50+"
Almost half (281) of the patients with severe and
moderately severe haemophilia had a score of l to 7 of a
total of 48 points. One in every three patients with
severe haemophilia had nine or more points, which
implies three joints with complete loss of all function or
several joints with minor damage. To illustrate the
impact of the severity of haemophilia we calculated in
the figure the median score of joint impairment for
severe, moderately severe, and mild haemophilia. The
median score on joint impairment was highest in the
older age groups.
Use of hospital facihlies—In 1985 the average use of
inpatient hospital facilities was four days per patient a
236 BMJ
year in the group with severe and moderately severe
haemophilia compared with one day for the general
Dutch male population. In 1972 this difference was
still 21 days. In 1972 one out of every two patients
needed to go to hospital, in contrast to one out of every
four in 1985. For those who went into hospital the
average number of days spent in hospital dropped from
49 days in 1972 to 16 days in 1985, which was near to
the national average of 13 days for men (table III).
ΓΑΒΙ l· in — Use ofinpaneni hospital facihties Jorpatients wilh severe
and moderatelv severe haemophilia
1972 1978 1985
(n = 242) (n=351) (n = 559)
Avcragc hospital use (numbcr of days
per patient a ycar)
Mo (%) of patients rcqumng
admission to hospital
Average duration of admission fnumber
of days per patient a ycar)
23 (2)*
114(47)
49 (20)*
10 (2)*
129(37)
26(15)*
4 (1)*
126(23)
16(13)*
*Figures for the general male population
The number of transfusions performed at hörne rose
from 996 in 1972 to 29680 in 1985. Therefore, the
number of outpatient visits to the hospital decreased
substantially.
Social participation—Table IV shows the improve-
ment in social participation, äs judged by absence from
school and work. The educational level of the survey
TABLt IV—Absence from school and work ofpanents with severe and
moderately severe haemophilia
1972 1978 1985
(n=242) (n = 351) (n = 559)
Average duration of absence from school
due to haemophilia (number of days
per patient a year)
No of respondents at school
Average duration of sick leave from work
(number of days per patient a year)
No of respondents with a job
36
105
32(18)*
91
19
163
34(18)*
114
9
196
20(15)*
215
*Figures for the general male population; national figures are not available
for school absence
population in 1985 was not different from that of the
general male population. For the respondents aged
between 15 and 64 years who had finished their
education, table V shows the participation in the
national labour force. The number of Dutch men who
do not work owing to unemployment or disablement
has grown substantially over the past 15 years.
TABLE v—Parlicipanon m the national workforce of respondents aged
15 to 64 years with severe and moderately severe haemophilia
1972(n=113) 1978 (n= 168) 1985(n=330)
No (%) aetive
No (%) mactivc
Relative mauivity ratio
(haemophihacs to
non-hacmophihacs)
89 (79) (91)*
24(21) (9)*
2 3
116 (69) (85)*
5 2 ( 3 1 ) ( 1 5 ) *
2 1
215(65 ) (77 )*
115(35) (23)*
1 5
*Figurcs tor the general Dutch male population Not mcludcd arc those
respondents who still reeeivc füll time education.
Although the same tendency was seen for the haemo-
philiacs, the difference between the patients and the
general male population decreased. This is shown by
the relative inactivity ratio which dropped from 2-3 in
1972 to l -5 in 1985. In all three surveys unemployment
among haemophiliacs was lower than the national
average, but the percentage of haemophiliacs with a
disablement pension was higher than in the general
male population.' Higher disablement figures were
found especially in the older age groups, reflecting
more severe joint impairment.
Discussion
In The Netherlandb we have no central registry of
medical or other data on patients with haemophilia.
By means of postal surveys we got an overview of
the medical and social circumstances of Dutch
haemophiliacs and were able to observe the changes
that occurred from 1972 to 1985. Of a possible
1250 patients with haemophilia in The Netherlands we
reached 935 patients (75%) in our last survey.
The relative mortality in haemophilia is low and
indicates a life expectancy that is almost in the normal
ränge. The relative mortality is now the same äs
that caused by Smoking cigarettes.1' These results
correspond well with recent data from Sweden" and
the United States.14 It must be feared, however, that
these figures will be affected negatively by mortality
from infection with HIV and liver disease.
Although measures have been taken to prevent HIV
infection, many haemophiliacs were infected before
these could be implemented.15 A prevalence of
seropositive patients here of 17% is low compared with
50% in France," 53% in West Germany,1' 39% in the
United Kingdom,18 and 80% in the United States." It is
higher, however, than in Belgium, 4%2° or Finland,
1-5% (E Ikkala, personal communication). The
low numbers of seropositive patients in these two
countries and The Netherlands can be explained by the
predominant use of plasma products from local unpaid
donors.
Many haemophiliacs are still unable to participate
fully in employment owing to joint impairment. We
expect that in the future this Situation will improve äs
more and more young haemophiliacs grow up with
better joints and muscles than the older haemophiliacs
did. A much longer observation period will be needed,
however, to see if this expectation becomes reality, so
that the 1985 level of joint impairment in patients with
severe haemophilia will diminish to the level of those
with moderately severe haemophilia äs shown in the
figure. Of course, the number of disabled persons in
the workforce will always be dependent on the general
economic Situation and the attitude of society towards
them.
Smith et al pointed out the encouraging results of
comprehensive haemophilia care programmes in the
United States. They concluded that the properly
treated employed patient can generate more money
than his treatment costs.' Schimpf and Niederberger
showed in a group of German haemophiliacs that the
employed patient would be able to make up roughly
half the cost of treatment through contributions to the
gross national product and pension savings.'1 For
The Netherlands we estimate that with an average
consumption of 54 000 units of factor VIII a year the
cost ($24 300) is more than the average annual income
of a Dutch man ($21 900). The difference in outcome
between these studies is caused by the, difference
in cost per unit of factor VIII in the United States
($0-10-0-12) and in Europe ($0-40-0-50)." These
differences in cost and other marketing strategies make
it difficult to make meaningful cost calculations.21
Nevertheless, our findings show the improvement of
the main medical and social indicators which provide
quantitative support for the general impression that
the introduction of modern clotting factor concentrates
in the late 1960s followed by prophylaxis and home
treatment have greatly improved the life expectancy
and the quality of life of haemophiliacs and their
families. The non-material gains such äs less pain and
discomfort and an improved social life would justify
the cost of modern replacement treatment even in the
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absence of the savings due to fewer admissions to
hospital, less absenteeism from work or school, and
lower social security payments. It is difficult to judge
the success of the treatment without considering the
disastrous AIDS epidemic, but the favourable trends
shown by our results give us a glimpse of the promises
held by the newer products and methods for the
treatment of haemophiliacs.
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